The European Union’s (EU) drug regulator, the European Medicines Agency (EMA), announced that it has started to evaluate the BioNTech-Pfizer vaccine developed against the new type of corona virus (Kovid-19) for the approval of use in the 12-15 age group.
According to the statement made by EMA, the evaluation process, which started after the application made for the vaccine called “Comirnaty” to be used in children aged 12-15, is expected to be completed in June.
In the “accelerated” evaluation process of the vaccine, the results of clinical studies involving adolescents older than 12 years will be examined.
AVAILABLE FOR 16 AND OVER
The vaccine is currently available for people aged 16 and over. The vaccine used in the prevention of Covid-19 disease contains a molecule called “mRNA”.
This molecule contains the “instruction” for producing the “spike” protein found naturally in the SARS-CoV-2 virus that causes the disease. The vaccine thus prepares the body to defend against disease.
The BioNTech-Pfizer vaccine was approved by the EU in December 2020, and the use of the vaccine started at the beginning of the year.